Proteins and proteomics
Proteomics reveals protein shifts in diabetic eye disease
Using proteomics, researchers identified protein changes in eye fluid that mark diabetic retinopathy progression and may serve as biomarkers for vision-threatening complications. Read more about this recent MCP paper.
Protein modifications drive lung cancer resistance
New assay enriches protein modifications in a single process, enabling detection of key changes in drug-resistant lung cancer cells that may guide future therapies.
How antigen-processing proteins shape immunity
Researchers show how components of the antigen processing machinery shape the immunopeptidome, offering insights into immune regulation and cancer biology.
New chemical strategy boosts accuracy in proteomics
Researchers develop a methylamine-based method that nearly eliminates peptide overlabeling in proteomics, improving accuracy in protein identification and quantitation.
Understanding the roles of extracellular matrix and vesicles in valvular disease
MOSAIC scholar Cassandra Clift uses mass spectrometry and multiomics to study cardiovascular calcification and collagen dysregulation, bridging her background in bioengineering and biology to investigate extracellular vesicles and heart disease.
Spider-like proteins spin defenses to control immunity
Researchers from Utrecht University discovered two distinct binding modes of a spider-shaped immune inhibitor found in serum.
Training AI to uncover novel antimicrobials
Antibiotic resistance kills millions, but César de la Fuente’s lab is fighting back. By pairing AI with human insight, researchers are uncovering hidden antimicrobial peptides across the tree of life with a 93% success rate against deadly pathogens.
AI-designed biomarker improves malaria diagnostics
Researchers from the University of Melbourne engineered Plasmodium vivax diagnostic protein with enhanced yield and stability while preserving antibody-binding, paving the way for more reliable malaria testing.
Matrix metalloproteinase inhibitor reduces cancer invasion
Scientists at the Mayo Clinic engineered a TIMP-1 protein variant that selectively inhibits MMP-9 and reduces invasion of triple-negative breast cancer cells, offering a promising tool for targeted cancer research.